3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
16
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Hypertension, Portal
1
Hepato Cellular Carcinoma
1
Hematologic Neoplasms
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
Gemcitabine
10
Mitomycin
6
Docetaxel
5
erdafitinib
4
durvalumab
4
BCG Vaccine
4
dodecyl maltoside
3
Cystoscopy
3
ALT-803
2
viscum album peptide
1
tremelimumab
1
pirarubicin
1
monalizumab
1
hydroxycamptothecinum
1
chondroitin sulfate, sodium hyaluronate drug combination
1
Watchful Waiting
1
Transurethral Resection of Bladder
1
Patient Discharge
1
Mitozytrex
1
Magnetic Resonance Spectroscopy
1
Injections
1
Hyaluronic Acid
1
House Calls
1
Home Care Services
1
Epirubicin
1
Drainage
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Chondroitin Sulfates
1
Accelerometry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
tremelimumab
×
90 days
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled